| Abstrakt: |
A recent study conducted by the Leiden Academic Center for Drug Research in the Netherlands has found that inhibiting the immunoproteasome, a variant of the proteasome that plays a role in antigen presentation, can reduce atherosclerosis and metabolic syndrome in mice. The researchers used ONX-0914, an inhibitor of the immunoproteasomal catalytic subunits, and observed a significant reduction in atherosclerosis, dendritic cell and macrophage levels, and antigen-experienced T cells. Additionally, the treatment led to a decrease in white adipose tissue mass and improvements in markers of metabolic syndrome. The study suggests that immunoproteasomal inhibition could be a new target for drug development in the treatment of atherosclerosis. [Extracted from the article] |
